Healthcare
WuXi Biologics (Cayman) Inc.(WXIBF)
Live Price
Offline$4.40
+0.00% today
1Y Change
+35.38%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $124.50B
- Revenue Growth
- +13.7%
- EPS Growth
- +45.1%
- Dividend Yield
- 0.0%
Coverage: 251 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
WuXi Biologics (Cayman) Inc. (WXIBF) is a Healthcare stock with a market cap of $124.50B and listed on OTC. The stock last traded around $4.40 and up 35.4% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +13.7%, EPS growth of +45.1%, a dividend yield of 0.0%. What stands out right now is revenue +13.7%, EPS +45.1%, free cash flow +117.4% with operating margin 30.5% and ROIC 9.2%. Valuation sits in the middle of the pack at P/E 24.6 and price/sales 5.8. Stock Foundry combines WXIBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+13.7% vs +7.6% peer median
Operating Margin
Above sector median
+30.5% vs +19.4% peer median
P/E
Below sector median
24.6 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2026 was reported on Mar 24, 2026 with revenue ahead of estimates by 0.0%.
The operating story is still moving forward
Revenue is running at +13.7% and EPS at +45.1%, with operating margin around 30.5%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 26, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 24, 2026 | +0.0% | +0.0% | +0.0% | +0.0% |
2025 Aug 19, 2025 | +24.1% | +0.0% | +14.3% | +29.9% |
2025 Mar 25, 2025 | -0.1% | +0.0% | -2.2% | +11.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WXIBF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
WXIBF Max Drawdown
-30.43%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for WXIBF and SPY.
Company Overview
WuXi Biologics (Cayman) Inc.
Other OTC
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
- Leadership
- Zhisheng Chen
- IPO Date
- Jan 30, 2018
- Employees
- 12.6k
- Street Address
- No. 108, Meiliang Road
- Mailing
- Wuxi, 214092
- Region
- Wuxi, CN
- Reporting Currency
- USD
- Investor Line
- +86 510 8183 5000
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 24.6
- EV/EBITDA
- 14.5
- Price/Sales
- 5.8
- Price/Book
- 2.5
Growth
- Revenue
- +13.7%
- EPS
- +45.1%
- Free Cash Flow
- +117.4%
Profitability
- Gross Margin
- 46.0%
- Operating Margin
- 30.5%
- Net Margin
- 22.5%
- ROE
- 10.6%
- ROIC
- 9.2%
Balance Sheet
- Debt/Equity
- 0.07
- Current Ratio
- 3.14
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.